Peptides DB
Research-centric peptide and protocol reference hub
Study 2 of 2Retatrutide (LY3437943) literatureBMJ (Clinical research ed.)Top journal2026

Retatrutide: Obesity drug opens to "compassionate use" in US after speculation Trump took it.

Not reported in abstract.

Read at BMJ (Clinical research ed.)Add to compare

Where it sits

this study against the rest of the retatrutide (ly3437943) corpus
2
Preclinical · this one
0
Observational
0
Open-label
0
Randomised
0
Reviews

Summary and findings

Not reported in abstract.

How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Retatrutide (LY3437943) corpus

DBeyond weight loss: multisystem benefits of obesity medications.The lancet. Diabetes & endocrinology · 2026